Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
ScemblixⓇ strong sales growth driven by underlying demand and
increasing recognition of efficacy and tolerability benefit
GROWTH
Sales evolution
USD m
Ex-US
US
SCEMBLIX®
(asciminib) 20 mg, 40 mg tablets
106
Q2 sales reflect strong demand from CML patients
resistant or intolerant to 2 or more prior TKIs
US new patient share in 3L+ at 35%¹; average # of
monthly prescribers +16% vs. Q1 2023
Global rollout ongoing with strong performance in
Germany & Japan
Despite available therapies (1st and 2nd generation
TKIs), strong unmet need remains in CML2
ASC4FIRST (1L registrational study) completed
enrollment, readout and filing expected 2024
28
76
15
52
41
10
31
4
78
61
37
42
29
Q2
Q3
Q4
Q1
Q2
2022
2023
1. IQVIA: US April 2023 rolling three months 3L+ new patient start share. 2. Survey on unmet needs in CML at EHA: reveals the need for treatment decisions that balance quality of life, efficacy, and tolerability goals; Chronic Myeloid
Leukemia Survey on Unmet Needs (CML SUN).
14 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation